By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Brittain, Harry G.; Felice, Philip V., filed on May 21, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Theaprin Pharmaceutic
By a News Reporter-Staff News Editor at Biotech Week Alexion Pharmaceuticals, Inc. announced that Max Link, Ph.D., Chairman of the Board of Directors of Alexion, passed away unexpectedly on October 5 while traveling on business. Dr. Link, a globally respected leader of companies in the pharmaceutical, biotechnology and medical device industries o
Arch Biopartners reported the introduction of Metablok, a new drug candidate in its development pipeline as a potential treatment for sepsis and cancer metastasis. Jennifer Rahn and their University of Calgary colleague, Dr. Arch Biopartners is a portfolio based biotechnology company.
Under the terms of the agreement, Bavarian Nordic will grant Janssen an exclusive license for its multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus. In addition, Bavarian Nordic will scale up its production and is targeting to manufacture more than 1 million doses of the vaccine valued at U
*Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson& Johnson licenses MVA-BN-based Ebola/ Marburg vaccine from Bavarian Nordic* Bavarian Nordic will scale up and is targeting to manufacture more than 1 million doses of the prophylactic vaccine in 2015 for clinical trials and emergency use in the current Ebola outbreak in W
By a News Reporter-Staff News Editor at Biotech Week Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced that the company has been awarded a $1.5 million Small Business Innovation Research Phase II contract from the National Cancer Institute to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma1
By a News Reporter-Staff News Editor at Biotech Week Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1 b patients in the United States and
According to a media release, the financing was led by Fosun Pharma joined by existing investors; General Electric Ventures, Pontifax, Docor, Counterpoint, together with MNS and several additional investors. This funding will help support our efforts to complete the clinical development of our system, continue our European clinical studies and file
By a News Reporter-Staff News Editor at Biotech Week A researcher at the Cancer Therapy& Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food& Drug Administration. The FDA's four-year grant will allow Andrew Brenner, M.D., Ph.D. to continue the study how the drug TH-302 may help people with
By a News Reporter-Staff News Editor at Biotech Week Export Development Canada announced financing for Toronto- based Merus Labs for their acquisition of an established pharmaceutical product in several European countries. EDC is Canada's leading provider of financing and insurance for small Canadian businesses with sales or business in other...
By a News Reporter-Staff News Editor at Biotech Week EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, The Institute of Cancer Research, and the Wellcome Trust, London, announced a co-development and license agreement building on two independent research programs at both the ICR and EMD Serono to identify inhibitors of
By a News Reporter-Staff News Editor at Biotech Week Vivolux, a pharmaceutical company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. The clinical study will be conducted in collaboration with the Memori
Ferring Pharmaceuticals Inc. Receives FDA Approval For New Cranberry Flavor Of PREPOPIK Sodium Picosulfate, Magnesium Oxide, And Anhydrous Citric Acid. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. Gastroenterology business unit at Ferri
By a News Reporter-Staff News Editor at Biotech Week- Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, announced the appointment of Marina Hahn as President of Consumer Goods, and the appointment of Elizabeth Woo as Vice President of Investor Relations and Corporate...
By a News Reporter-Staff News Editor at Biotech Week- Based on its recent analysis of the biopharmaceutical contract manufacturing industry, Frost& Sullivan recognizes IDT Biologika with the 2014 Europe Frost& Sullivan Award for Customer Service Leadership. IDT Biologika's high-quality customer care, best-in-class practices, and innovative...
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency has granted orphan designation to GW's investigational product Epidiolex in the treatment of Dravet syndrome, a rare.
By a News Reporter-Staff News Editor at Biotech Week Halozyme Therapeutics, Inc. announced the issuance of U.S. Helen Torley, President and CEO. The issued U.S. patent is anticipated to expire on October 28, 2032, which includes the patent term adjustment.
By a News Reporter-Staff News Editor at Biotech Week Halozyme Therapeutics, Inc. announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of Sciences symposium "Targeting Key Vulnerabilities in Pancreatic Cancer," being held on October 9, 2014 in New York City. "These data in animal models support our ongoing Phase 2
ALEXANDRIA, Va., Oct. 22 IBC Pharmaceuticals, Morris Plains, New Jersey, has been assigned a patent developed by four co-inventors for "methods and compositions for generating bioactive assemblies of increased complexity and uses." The co-inventors are Chien-Hsing Chang, Downingtown, Pennsylvania, David M. Goldenberg, Mendham, New Jersey, William
By a News Reporter-Staff News Editor at Biotech Week Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics, announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. "Thus, the superior d
Insys Therapeutics, Inc. reported that its Food and Drug Administration inspected and Drug Enforcement Agency approved facility in Round Rock, Texas, has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol. Insys believes these quantities are sufficient to pursue its CBD development program as currently planned.
Insys submitted an NDA to the FDA for its proprietary Dronabinol Oral Solution in August 2014. According to the FDA letter and a subsequent informal meeting with the FDA, Insys provided an inadequate or incomplete pediatric study plan to conduct studies to assess the safety and effectiveness of Dronabinol Oral Solution in pediatric patients.
Johnson& Johnson today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health, combine
By a News Reporter-Staff News Editor at Biotech Week The FDA's grant of permission of "expanded access" to Tekmira to administer an experimental medicine for Ebola highlights not only the grave threat the disease outbreak presents, but also the difficulty of bringing life-saving products such as vaccines to market, according to Kalorama Informati
Masimo reported that a new clinical study evaluating Masimo's latest noninvasive patient monitoring parameter, Oxygen Reserve Index ORI, showed that ORI can provide advanced warning of potential hypoxia and may help clinicians optimize oxygenation before and during prolonged intubation. At the University of Texas Southwestern and Children's Medical